Coherus BioSciences (CHRS) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CHRS Coherus BioSciences

Watchlist

1.370
+0.150+12.30%

Close Dec 2 16:00 ET

2.160
+0.790+57.66%

Pre 09:11 ET

157.84MMarket Cap-15222P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Coherus Announces Agreement to Divest UDENYCA Franchise for up to $558 Million to Intas Pharmaceuticals Ltd.
GlobeNewswire07:00 ET
Sector Update: Health Care
MT Newswires16minutes ago
Coherus Biosciences to Sharpen Fcous on Immuno-oncology Portfolio
TipRanks07:10 ET
Coherus: Post-Closing Proceeds to Repay All of $230M Convertible Notes Due April 2026
Dow Jones07:05 ET
Coherus BioSciences: Proceeds to Fund Development of LOQTORZI Combination Programs
Dow Jones07:04 ET
Express News | Coherus Announces Agreement to Divest Udenyca® Franchise for up to $558 Million to Intas Pharmaceuticals Ltd.
Reuters07:00 ET

Comments

Jaguar8

2 hours ago

NEWS

$Coherus BioSciences (CHRS.US)$
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
7 minutes ago, 4:00 AM PST
Via GlobeNewswire
CHRS
Share
- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor -
- Proceeds to fund development of key combination programs with LOQTORZI, including casdozokitug, a first-in-class, cli...